Target intelligence / Profile preview

Myosin light chain kinase 2, skeletal muscle (MYLK2)

Target
MYLK2
Molecular classification
Enzyme, Serine/threonine protein kinase, Calcium/calmodulin-dependent protein kinase
01

Overview

Myosin light chain kinase 2, skeletal muscle (MYLK2) is a calcium/calmodulin-dependent serine/threonine protein kinase specifically and abundantly expressed in adult skeletal muscle, particularly in fast-twitch fibers[2][3][5]. It catalyzes the phosphorylation of the regulatory light chain of sarcomeric myosin at Ser15 in response to increases in intracellular calcium, a process that modulates the rate and sensitivity of muscle contraction and contributes to the potentiation of force generation during repetitive stimulation. MYLK2 is critical for normal muscle function and adaptation, and mutations in the MYLK2 gene are linked to certain forms of familial hypertrophic and dilated cardiomyopathy[5]. As an enzyme central to contraction regulation in skeletal muscle, MYLK2 represents a potential therapeutic target for disorders of muscle contractility, although at present, no clinically approved drugs specifically target MYLK2[2][3][5].

Other names
Myosin light chain kinase 2, skeletal/cardiac muscleMYLK2MLCK2skMLCKKMLCMLCKskeletal muscle myosin light chain kinase
02

Mechanism of action

Drugs targeting MYLK2 would inhibit calcium/calmodulin-dependent phosphorylation of myosin regulatory light chain, thereby altering muscle contractility

03

Biological functions

Phosphorylation of myosin regulatory light chainModulation of skeletal muscle contractionRegulation of muscle force potentiation and fatigue responses
04

Disease associations

Cardiomyopathy (familial hypertrophic)Dilated cardiomyopathyPotential role in muscle fatigue and performance disorders
05

Safety considerations

Inhibition may lead to muscle weakness or impaired contractilityGenetic variants may predispose to cardiomyopathies or other myopathic conditions
06

Biomarkers

MYLK2 mutations as a marker for inherited cardiomyopathiesMyosin regulatory light chain phosphorylation status may serve as a surrogate biomarker for MYLK2 activity

Beyond the preview

Go deeper on Myosin light chain kinase 2, skeletal muscle (MYLK2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Myosin light chain kinase 2, skeletal muscle (MYLK2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call